Simultaneous quantification of rosiglitazone and its two major metabolites, N-desmethyl and p-hydroxy rosiglitazone in human plasma by liquid chromatography/tandem mass spectrometry: Application to a pharmacokinetic study

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 877, Issue 20-21, 2009, Pages 1951-1956

  Kim, Kwon Bok ^a   Lee, Dong Jun ^b   Yeo, Chang Woo ^a   Shin, Jae Gook ^a,b   Bae, Soo Kyung ^a,b  

^a Inje University College of Medicine   (South Korea)

^b Inje University College of Medicine   (South Korea)

Author keywords

Human plasma; LC MS MS; N desmethyl rosiglitazone; p Hydroxy rosiglitazone; Rosiglitazone

Indexed keywords

HUMAN PLASMA; LC-MS/MS; N-DESMETHYL ROSIGLITAZONE; P-HYDROXY ROSIGLITAZONE; ROSIGLITAZONE;

ACETONITRILE; CHROMATOGRAPHIC ANALYSIS; ELECTROSPRAY IONIZATION; HIGH PRESSURE LIQUID CHROMATOGRAPHY; LIQUIDS; MASS SPECTROMETERS; MASS SPECTROMETRY; METABOLISM; METABOLITES; ORGANIC ACIDS; PHARMACOKINETICS; PLASMA (HUMAN); SPECTRUM ANALYSIS;

PLASMAS;

4 HYDROXY ROSIGLITAZONE; ACETONITRILE; CARBON; CYTOCHROME P450 2C8; FORMIC ACID; N DESMETHYL ROSIGLITAZONE; ROSIGLITAZONE; UNCLASSIFIED DRUG;

ARTICLE; HALF LIFE TIME; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETER; METABOLITE; NORMAL HUMAN; PARTICLE SIZE; PLASMA; PRIORITY JOURNAL; SEPARATION TECHNIQUE; STANDARD; TANDEM MASS SPECTROMETRY; VALIDATION STUDY; VOLUNTEER;

CHROMATOGRAPHY, LIQUID; HUMANS; HYPOGLYCEMIC AGENTS; MALE; TANDEM MASS SPECTROMETRY; THIAZOLIDINEDIONES;

EID: 67049134605     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2009.05.001     Document Type: Article

References (21)

1. Yki-Järvinen H. N. Engl. J. Med. 351 (2004) 1106
2. Balfour J.A., and Plosker G.L. Drugs 57 (1999) 921
3. Cox P.J., Ryan D.A., Hollis F.J., Harris A.-M., Miller A.K., Vousden M., and Ley H.C. Drug Metab. Dispos. 28 (2000) 772
4. Baldwin S.J., Clarke S.E., and Chenery R.J. Br. J. Clin. Pharmacol. 48 (1999) 424
5. Niemi M., Backman J.T., Granfors M., Laitila J., Neuvonen M., and Neuvonen P.J. Diabetologia 46 (2003) 1319
6. Hruska M.W., Amico J.A., Langaee T.Y., Ferrell R.E., Fitzgerald S.M., and Frye R.F. Br. J. Clin. Pharmacol. 59 (2005) 70
7. Pedersen R.S., Damkier P., and Brosen K. Br. J. Clin. Pharmacol. 62 (2006) 682
8. Dai D., Aeldin D.C., Blaisdell J.A., Chanas B., Coulter S.J., Ghanayem B.I., and Goldstein J.A. Pharmacogenetics 11 (2001) 597
9. Kolte B.L., Raut B.B., Deo A.A., Bagool M.A., and Shinde D.B. J. Chromatogr. B 788 (2003) 37
10. Muxlow A.M., Fowles S., and Russell P. J. Chromatogr. B 752 (2001) 77
11. Mamidi R.N., Chaluvadi M.R., Benjamin B., Ramesh M., Katneni K., Babu A.P., Bhanduri J., Rao N.M., and Rajagopalan R. Arzneimittelforschung 52 (2002) 560
12. Radhakrishna T., Satyanarayana J., and Satyanarayana A. J. Pharm. Biomed. Anal. 29 (2002) 873
13. Hrusak M.W., and Frye R.F. J. Chromatogr. B 803 (2004) 317
14. Pedersen R.S., Brosen K., and Nielsen F. Chromatographia 62 (2005) 197
15. Kim K.A., and Park J.Y. Biomed. Chromatogr. 18 (2004) 613
16. He J., Hu Y.F., Duan L.F., Tan Z.R., Wang L.S., Wang D., Zhang W., Li Z., Liu J., Tu J.H., Yao Y.M., and Zhou H.H. J. Pharm. Biomed. Anal. 43 (2007) 580
17. O'Maille G., Pai S.M., Tao X., Douglas Jr. G.T., and Jenkins R.G. J. Pharm. Biomed. Anal. 48 (2008) 934
18. US FDA. Guidance for Industry/Bioanalytical Method Validation (2001), US Food and Drug Administration, Rockville, MD
19. Matuszewski B.K., Constanzer M.L., and Chavez-Eng C.M. Anal. Chem. 75 (2003) 3019
20. Chiou W.L. J. Pharmacokinet. Biopharm. 6 (1978) 539
21. Cox P.J., Ryan D.A., Hollis F.J., Harris A.-M., Miller A.K., Vousden M., and Cowley H. Drug Metab. Dispos. 28 (2000) 772